Paliperidon Teva
Paliperidone Palmitate Once-Monthly Depot Injection for Schizophrenia
Paliperidon Teva is a generic long-acting injectable (LAI) antipsychotic medicine containing paliperidone palmitate. It is licensed for the maintenance treatment of schizophrenia in adults whose illness has already been stabilised on oral paliperidone or risperidone, and for the treatment of schizoaffective disorder. Because the medication is administered as a once-monthly intramuscular depot injection, it helps maintain steady drug levels, reduces the need for daily tablet-taking, and significantly lowers the risk of relapse and rehospitalisation. Paliperidon Teva is bioequivalent to the originator product marketed internationally as Xeplion (European Union) or Invega Sustenna (United States).
Quick Facts: Paliperidon Teva
Key Takeaways
- Paliperidon Teva is a once-monthly intramuscular depot injection that delivers the atypical antipsychotic paliperidone, the major active metabolite of risperidone, in a long-acting palmitate ester form.
- It is used for the maintenance treatment of schizophrenia and is particularly beneficial for patients who have difficulty adhering to daily oral medication – a common and clinically significant problem in schizophrenia.
- Treatment begins with a two-dose initiation regimen: 150 mg on day 1 and 100 mg on day 8, both administered in the deltoid muscle, followed by a monthly maintenance injection of 25 to 150 mg into either the deltoid or gluteal muscle.
- Key risks include extrapyramidal symptoms (parkinsonism, akathisia, dystonia), metabolic changes (weight gain, dyslipidaemia, hyperglycaemia), hyperprolactinaemia, QT prolongation, orthostatic hypotension, and a small increased mortality risk in elderly patients with dementia-related psychosis.
- Because the depot provides sustained plasma paliperidone levels for up to 18 weeks, any adverse reactions or dose adjustments will take weeks to fully resolve – careful patient selection and oral tolerability testing are therefore recommended before the first injection.
What Is Paliperidon Teva and What Is It Used For?
Paliperidon Teva belongs to the class of medicines known as atypical (second-generation) antipsychotics. The active substance is paliperidone palmitate, an ester prodrug of paliperidone. Paliperidone itself (also known as 9-hydroxyrisperidone) is the major active metabolite of risperidone and has been available as an oral extended-release tablet for many years. The palmitate ester makes the molecule highly lipophilic and poorly water soluble, allowing it to be formulated as a nanocrystal aqueous suspension that is slowly released from the injection site over several weeks.
The long-acting injectable formulation was first approved by the European Medicines Agency (EMA) in 2011 under the brand name Xeplion and by the U.S. Food and Drug Administration (FDA) under the brand name Invega Sustenna. Paliperidon Teva is a generic version of this once-monthly formulation that became available in European markets after expiry of the originator product's market protection. Because it is authorised through a generic pathway with demonstrated bioequivalence, the clinical effects, dosing schedule, and safety profile are considered essentially the same as the originator.
The approved indications for Paliperidon Teva include:
- Maintenance treatment of schizophrenia in adults whose condition has been stabilised with paliperidone or risperidone. It is particularly suitable for patients with a history of poor adherence to daily oral medication, frequent relapses, or difficulty organising a regular medication routine.
- Treatment of schizoaffective disorder in adults, either as monotherapy or in combination with mood stabilisers or antidepressants. This indication is explicitly recognised in the FDA prescribing information and is often used off-label in the European Union based on robust clinical trial data.
Unlike oral antipsychotics, which require a patient to remember a daily tablet and to actively swallow it each day, a once-monthly injection removes several recurring decision points. Peer-reviewed evidence consistently shows that patients using long-acting injectables such as paliperidone palmitate experience fewer relapses, fewer psychiatric hospitalisations, and better functional outcomes compared with their previous oral treatment, particularly during the first years after diagnosis when adherence is typically lowest.
Paliperidone is a potent antagonist at dopamine D2 receptors in the mesolimbic pathway, where excess dopamine signalling is thought to underlie the positive symptoms of psychosis (hallucinations, delusions, disorganised thinking). It is simultaneously a potent antagonist at serotonin 5-HT2A receptors, which modulates dopamine signalling in other brain regions and helps protect against the extrapyramidal (movement) side effects typical of older, purely dopamine-blocking drugs. Paliperidone also binds to alpha-1 and alpha-2 adrenergic receptors and H1 histamine receptors, which explains side effects such as orthostatic hypotension and sedation.
A distinctive feature of paliperidone compared with many other antipsychotics is its very limited hepatic metabolism. Approximately 59 percent of a dose is excreted unchanged in the urine, with the remainder undergoing only minor metabolism through CYP2D6 and CYP3A4. This renal-dominant elimination has two important implications: drug interactions mediated by the liver cytochrome P450 system are generally less of an issue than with risperidone or aripiprazole, but dose reduction is required in patients with moderate to severe renal impairment.
What Should You Know Before Starting Paliperidon Teva?
Before initiating Paliperidon Teva, a thorough discussion with the prescribing psychiatrist about full medical history, current medications, allergies, and social circumstances is essential. Because the depot injection provides drug cover for a full month and remains detectable for several months after the last dose, decisions about starting therapy should not be taken lightly, and patients should already be established on oral paliperidone or risperidone with adequate tolerability before the first injection.
Contraindications
Paliperidon Teva must not be used in patients with known hypersensitivity to paliperidone, risperidone, or to any of the excipients of the injection. Because paliperidone is the active metabolite of risperidone, patients with a history of true hypersensitivity to risperidone should also avoid paliperidone preparations. Signs of a hypersensitivity reaction include rash, urticaria, swelling of the face, lips, tongue or throat, and difficulty breathing, and require immediate emergency medical attention.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs, including paliperidone palmitate, are at an increased risk of death and cerebrovascular adverse events (stroke, transient ischaemic attack). Paliperidon Teva is not approved for the treatment of dementia-related psychosis and should not be used in this population. Observed increased mortality is primarily related to cardiovascular events (for example, sudden death) and infections (for example, pneumonia).
Warnings and Precautions
Inform the prescribing physician about any of the following conditions before the first injection, as they may require additional monitoring, dose adjustment, or an alternative treatment:
- Cardiovascular disease: Including any history of QT prolongation, arrhythmia, myocardial infarction, heart failure, or family history of sudden cardiac death. Paliperidone may prolong the QT interval and should be used with caution alongside other QT-prolonging drugs. Baseline and periodic ECG monitoring may be advisable.
- Electrolyte imbalances: Correction of hypokalaemia and hypomagnesaemia is recommended before starting treatment, as these electrolyte disturbances increase the risk of torsade de pointes.
- Diabetes, prediabetes or risk factors for diabetes: Hyperglycaemia and new-onset diabetes have been reported with all atypical antipsychotics. Baseline fasting glucose or HbA1c, followed by regular metabolic monitoring, is recommended.
- Dyslipidaemia and obesity: Lipid profile and weight should be recorded at baseline and monitored throughout treatment. Lifestyle support should be integrated into the care plan from the outset.
- Renal impairment: Because paliperidone is primarily cleared by the kidneys, dose reduction is required for moderate renal impairment (creatinine clearance 50 to under 80 ml/min), and Paliperidon Teva is not recommended in severe renal impairment (creatinine clearance below 50 ml/min).
- Hepatic impairment: No dose adjustment is required for mild to moderate hepatic impairment. Paliperidone has not been studied in severe hepatic impairment.
- Parkinson's disease or dementia with Lewy bodies: These patients may be severely sensitive to dopamine antagonism, with a risk of neuroleptic malignant syndrome, worsening of motor symptoms, and confusion.
- Seizures: Paliperidone should be used with caution in patients with a history of seizures or conditions that lower the seizure threshold.
- Venous thromboembolism risk: Cases of VTE, including pulmonary embolism and deep vein thrombosis, have been reported with antipsychotics. Identify and minimise modifiable risk factors.
- Priapism: Although rare, paliperidone's alpha-adrenergic blocking activity can cause prolonged painful erection; patients should seek immediate medical attention if priapism occurs.
Because Paliperidon Teva provides drug cover for several months, it is strongly recommended that patients who have not previously taken paliperidone or risperidone first establish tolerability with an oral form. This allows any acute hypersensitivity, extrapyramidal, or cardiovascular reaction to be identified before committing to a long-acting depot. Specialist psychiatric advice should guide this decision.
Pregnancy and Breastfeeding
Women who are pregnant, planning a pregnancy, or breastfeeding should discuss treatment options with the prescribing psychiatrist before the first injection. The decision to continue antipsychotic treatment during pregnancy requires a careful weighing of the risks of relapse in untreated schizophrenia (which can itself harm both mother and foetus) against the known and unknown risks of medication exposure.
Neonates exposed to antipsychotic drugs, including paliperidone palmitate, during the third trimester of pregnancy are at risk of withdrawal and extrapyramidal symptoms after delivery. Reported symptoms include agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding difficulty. These symptoms are typically self-limiting but may require neonatal monitoring, and in some cases, intensive care. Because the injection provides drug cover for up to several months, any pregnancy exposure from an injection given shortly before or during early pregnancy cannot be easily reversed.
Paliperidone is excreted into human breast milk in small amounts. A risk to the breastfed infant cannot be excluded, and a decision whether to breastfeed or to continue treatment should be made taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Driving and Operating Machinery
Paliperidone can cause drowsiness, sedation, fatigue, dizziness, and visual disturbances. Patients should be advised not to drive or operate machinery until their individual response to the medication is known. This is particularly important in the first weeks after initiation and after any dose change.
How Does Paliperidon Teva Interact with Other Drugs?
Paliperidone has a relatively clean metabolic profile compared with many other psychotropic medications. Because roughly 59 percent of a dose is excreted unchanged in urine, and only a small fraction undergoes hepatic metabolism through CYP2D6 and CYP3A4, drug-drug interactions mediated by enzyme inhibition are usually modest. Interactions mediated by pharmacodynamic overlap (additive sedation, QT prolongation, hypotension, anticholinergic effects) are clinically more relevant and require careful consideration.
Major Interactions
The interactions below are considered clinically significant and typically require dose adjustments, avoidance, or specific monitoring:
| Interacting Drug / Class | Effect | Clinical Recommendation |
|---|---|---|
| Strong CYP3A4 / P-gp inducers (carbamazepine, rifampicin, phenytoin, phenobarbital, St. John's Wort) | Substantially decrease paliperidone plasma concentrations and may reduce efficacy | Re-evaluate dose on starting or stopping the inducer; a dose increase of Paliperidon Teva may be necessary during concomitant use |
| QT-prolonging drugs (amiodarone, sotalol, quinidine, methadone, moxifloxacin, citalopram >40 mg) | Additive QT prolongation with risk of torsade de pointes and sudden cardiac death | Avoid combination where possible; if unavoidable, obtain baseline and periodic ECG, correct electrolytes |
| Dopamine agonists (levodopa, pramipexole, ropinirole) for Parkinson's disease | Antagonistic effect: paliperidone blocks dopamine receptors and may worsen parkinsonism or trigger neuroleptic malignant syndrome | Avoid combination. If antipsychotic cover is essential in a patient with Parkinson's disease, specialist neuropsychiatric advice is required |
| CNS depressants (benzodiazepines, opioids, sedating antihistamines, alcohol) | Additive sedation, respiratory depression, and cognitive impairment | Use lowest effective doses; counsel patient about additive drowsiness and impaired driving |
| Antihypertensive medications | Enhanced blood pressure-lowering with increased orthostatic hypotension risk | Monitor standing and sitting blood pressure; titrate antihypertensives cautiously |
| Tramadol, bupropion and other drugs lowering seizure threshold | Increased risk of seizures | Use with caution, especially in patients with prior seizure history |
Other Notable Interactions
Several additional interactions warrant awareness when prescribing Paliperidon Teva:
- Risperidone: Paliperidone is the major active metabolite of risperidone, and combining the two results in duplicate therapy with additive dopamine D2 blockade. The combination is generally not recommended.
- Oral paliperidone extended-release tablets: Co-administration with Paliperidon Teva at initiation is not required for most patients, but a short overlap of a few days may occasionally be used under specialist supervision during transition from an oral regimen.
- Other long-acting injectable antipsychotics: Switching between long-acting injectables should be planned carefully to avoid periods of sub-therapeutic coverage or excessive D2 blockade.
- Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, MAO inhibitors): Risk of serotonin syndrome appears low with paliperidone itself but remains relevant when multiple serotonergic agents are combined.
- Alcohol: Should be avoided or strictly limited, as it worsens sedation, impairs cognition and judgement, and can destabilise the underlying psychiatric condition.
- Smoking: Unlike olanzapine and clozapine, paliperidone plasma concentrations are not significantly affected by cigarette smoking, which simplifies dose management in patients who smoke.
Always carry an up-to-date medication list, including the dates of each Paliperidon Teva injection, and show it to any new prescriber, pharmacist, dentist, or emergency doctor. Because the depot persists for many weeks, an interaction risk is not limited to the month of the most recent injection.
What Is the Correct Dosage of Paliperidon Teva?
The dosing of Paliperidon Teva follows the regimen established for paliperidone palmitate once-monthly across regulatory jurisdictions (EMA, FDA, MHRA, TGA). It is designed to achieve therapeutic plasma paliperidone levels rapidly, while allowing individual titration to balance efficacy against tolerability. All injections must be administered by a trained healthcare professional using proper intramuscular injection technique.
Adults – Initiation and Maintenance
| Treatment Phase | Dose | Injection Site | Timing |
|---|---|---|---|
| Initiation dose 1 | 150 mg | Deltoid muscle | Day 1 |
| Initiation dose 2 | 100 mg | Deltoid muscle | Day 8 (± 4 days) |
| Recommended maintenance | 75 mg | Deltoid or gluteal muscle | Monthly (every 28 days ± 7) |
| Maintenance dose range | 25 mg to 150 mg | Deltoid or gluteal muscle | Monthly, individualised |
| Moderate renal impairment (CrCl 50–79 ml/min) | 100 mg day 1, 75 mg day 8, then 50 mg monthly | Deltoid (initiation), then deltoid or gluteal | As above |
The two initiation doses are both given into the deltoid muscle, as this site provides faster initial paliperidone absorption than the gluteal site, allowing therapeutic plasma levels to be reached more quickly. After the second initiation dose, subsequent maintenance injections can be administered in either the deltoid or the gluteal muscle based on patient preference, body habitus, and local tolerability. Injections should alternate between sides to reduce local tissue reactions.
Patients already stabilised on oral paliperidone or risperidone can transition directly to Paliperidon Teva. The oral antipsychotic may usually be stopped at the time of the first Paliperidon Teva injection. For patients already stabilised on risperidone long-acting injectable, the first Paliperidon Teva injection is given in place of the next scheduled risperidone injection, followed by a second dose one month later with no need for repeat initiation dosing.
Children and Adolescents
Paliperidon Teva is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of the long-acting injectable form have not been established in this age group, and regulatory approval is restricted to adults.
Elderly Patients
In elderly patients with normal renal function (creatinine clearance at or above 80 ml/min), the same dose recommendations apply as for younger adults. Because renal function commonly declines with age, renal function should be estimated before starting treatment and periodically thereafter, and the dose adjusted according to creatinine clearance. As stated above, Paliperidon Teva must not be used in elderly patients with dementia-related psychosis due to an increased risk of death and stroke.
Missed or Delayed Doses
Delayed second initiation dose
If the day 8 initiation dose is given more than 4 days after the recommended timepoint, re-initiation may be required. Contact the prescribing team for specific guidance.
Delayed monthly maintenance dose (less than 6 weeks since last injection)
Resume the previous monthly dose as soon as practical, then continue with monthly injections thereafter.
Delayed monthly maintenance dose (6 weeks to 6 months since last injection)
The previous monthly maintenance dose should be resumed as soon as possible, followed a week later by the same dose in the deltoid, and then normal monthly dosing thereafter.
Delayed monthly maintenance dose (more than 6 months since last injection)
Re-initiate treatment as if starting anew, with 150 mg on day 1 and 100 mg on day 8 in the deltoid, followed by monthly maintenance.
Overdose
Because Paliperidon Teva is administered only by a trained healthcare professional, accidental overdose in the outpatient setting is rare. Potential signs include extrapyramidal symptoms, drowsiness, sedation, tachycardia, hypotension, QT prolongation, and seizures. Establish and maintain a clear airway, ensure adequate oxygenation, monitor cardiac rhythm continuously for QT prolongation and arrhythmia, and manage hypotension and electrolyte disturbances with intravenous fluids and vasopressors as clinically indicated. There is no specific antidote.
Because the sustained-release nature of the depot means that paliperidone continues to be released from the injection site for weeks, the clinical effects of an overdose may be prolonged and require extended observation. Extrapyramidal symptoms can be managed with anticholinergic agents. Activated charcoal is not useful given the parenteral administration route.
What Are the Side Effects of Paliperidon Teva?
Like all medicines, Paliperidon Teva can cause side effects, although not everyone experiences them. The adverse event profile is consistent with that of oral paliperidone and with other long-acting injectable paliperidone preparations such as Xeplion and Invega Sustenna. Because the depot provides several weeks of drug exposure after each injection, it is important to report emerging symptoms early so that they can be managed before the next dose.
Side effects below are grouped by frequency according to MedDRA conventions, based on clinical trial data and post-marketing surveillance reported to the European Medicines Agency and the FDA:
Very Common
May affect more than 1 in 10 people
- Insomnia
- Headache
- Upper respiratory tract infection
- Injection site reactions (pain, redness, swelling, induration, nodule formation)
- Weight gain
Common
May affect up to 1 in 10 people
- Extrapyramidal symptoms: parkinsonism (tremor, rigidity, slowness), akathisia (inner restlessness, inability to sit still), dystonia (muscle spasms)
- Somnolence and sedation
- Dizziness and orthostatic hypotension
- Anxiety, agitation and depression
- Tachycardia
- Hypertension
- Nausea, vomiting, abdominal pain, constipation, diarrhoea
- Dry mouth or excessive salivation
- Elevated prolactin, with or without breast discomfort, galactorrhoea, or menstrual disturbance
- Fatigue and asthenia
- Musculoskeletal pain (back pain, joint pain)
- Cough, nasal congestion
- Elevated hepatic enzymes (AST, ALT)
- Blurred vision
Uncommon
May affect up to 1 in 100 people
- Tardive dyskinesia (potentially irreversible involuntary movements of tongue, face or limbs)
- Seizures (convulsions)
- Syncope (fainting)
- QT interval prolongation on ECG
- Hyperglycaemia, new-onset or worsening diabetes mellitus
- Dyslipidaemia (increased cholesterol and triglycerides)
- Sexual dysfunction (erectile dysfunction, reduced libido, anorgasmia)
- Urinary incontinence or retention
- Aspiration pneumonia and dysphagia
- Sleep apnoea
- Thrombocytopenia, leukopenia, neutropenia
- Hypersensitivity reactions
- Pulmonary embolism and deep vein thrombosis
Rare or Frequency Not Known
Reported in post-marketing surveillance
- Neuroleptic malignant syndrome (hyperthermia, muscle rigidity, autonomic instability, altered consciousness)
- Diabetic ketoacidosis and hyperosmolar coma
- Anaphylactic reaction
- Angioedema
- Priapism
- Severe cutaneous adverse reactions including DRESS syndrome
- Rhabdomyolysis
- Inappropriate antidiuretic hormone secretion
- Water intoxication due to polydipsia
- Neonatal withdrawal syndrome in infants exposed in utero
- Intraoperative floppy iris syndrome during cataract surgery
High fever together with muscle stiffness, sweating and altered consciousness (possible neuroleptic malignant syndrome); uncontrollable movements of the tongue, face, or limbs (possible tardive dyskinesia); chest pain, shortness of breath, or leg swelling (possible pulmonary embolism or deep vein thrombosis); severe allergic reaction with swelling of the face, tongue or throat; a painful erection lasting more than four hours (priapism); or thoughts of self-harm or suicide.
Because the depot delivers paliperidone over many weeks, dose-related side effects such as extrapyramidal symptoms or prolactin elevation may be difficult to resolve quickly. When troublesome, the treating psychiatrist may lower the next monthly dose, add an anticholinergic agent for extrapyramidal symptoms, or, in some cases, switch to a different antipsychotic. All suspected adverse reactions should be reported to the prescribing physician and, where relevant, to the national pharmacovigilance authority.
How Should Paliperidon Teva Be Stored?
Because Paliperidon Teva is administered by a healthcare professional, patients generally do not need to store the medicine themselves. Pharmacies and clinics are responsible for cold-chain and controlled-temperature storage and for checking expiry dates before each administration. Nonetheless, it is helpful for patients to understand the storage principles, particularly if they transport the syringe from a pharmacy to an injection clinic.
- Temperature: Store below 30 degrees Celsius (86 degrees Fahrenheit). Paliperidon Teva is an aqueous nanocrystal suspension and must not be frozen, as freezing can disrupt the crystal structure and alter the release profile.
- Light protection: Keep the pre-filled syringe in its original carton until immediately before use to protect it from light.
- Handling: The syringe must be shaken vigorously for at least 10 seconds immediately before injection to ensure a homogeneous suspension. A cloudy appearance is normal; do not use if clumping, foreign particles, or cracks in the syringe are visible.
- Disposal: Any unused medicine, used syringes, or needles must be disposed of in compliance with local sharps and pharmaceutical waste regulations. Do not flush down the toilet or place in household waste.
- Expiry date: Do not use Paliperidon Teva after the expiry date stated on the outer carton and syringe label. The expiry date refers to the last day of the stated month.
Patients and caregivers who support the logistics of long-acting injectable therapy (for example, bringing the medicine from a community pharmacy to a nurse-led depot clinic) should confirm with the pharmacist whether additional temperature-controlled transport precautions are needed during hot weather.
What Does Paliperidon Teva Contain?
The active substance of Paliperidon Teva is paliperidone palmitate, which is hydrolysed in the body to release the pharmacologically active molecule paliperidone. Paliperidone is chemically identical to the major active metabolite of risperidone and was originally developed as a standalone oral antipsychotic (paliperidone extended-release tablets, originator brand Invega) before being reformulated as a long-acting palmitate ester for depot use.
Active Ingredient Content Per Pre-Filled Syringe
| Strength (paliperidone) | Equivalent paliperidone palmitate | Injection volume |
|---|---|---|
| 25 mg | 39 mg | 0.25 ml |
| 50 mg | 78 mg | 0.5 ml |
| 75 mg | 117 mg | 0.75 ml |
| 100 mg | 156 mg | 1.0 ml |
| 150 mg | 234 mg | 1.5 ml |
Inactive Ingredients (Excipients)
The aqueous suspension for injection typically contains the following excipients, which act as solubilisers, buffers, and tonicity agents:
- Polysorbate 20 – surfactant that keeps the nanosuspension stable
- Polyethylene glycol 4000 – viscosity-modifying agent
- Citric acid monohydrate – buffer
- Disodium hydrogen phosphate anhydrous – buffer
- Sodium dihydrogen phosphate monohydrate – buffer
- Sodium hydroxide – pH adjustment
- Water for injections – solvent
Paliperidon Teva contains less than 1 mmol (23 mg) of sodium per dose, meaning it is essentially sodium-free, which is relevant for patients on a sodium-restricted diet. The product does not contain gluten or lactose. Patients with a confirmed allergy to any of the excipients should discuss alternatives with their prescriber.
The appearance of the suspension is white to off-white. A homogeneous appearance after thorough shaking is required before injection; any sign of foreign particles or abnormal colour should prompt disposal of the syringe and replacement with a new unit.
Frequently Asked Questions About Paliperidon Teva
Paliperidon Teva is a once-monthly long-acting injection. After an initial two-dose loading regimen on day 1 and day 8, patients receive a maintenance injection once every month (every 28 days, with a tolerance window of plus or minus 7 days). This monthly schedule makes it a convenient option for patients who have difficulty remembering daily oral antipsychotic medication, and it supports treatment continuity in schizophrenia. Some patients, after at least four months of stable treatment, may be eligible to switch to a three-monthly or six-monthly paliperidone depot product, but these longer-interval preparations are separate medicines and require specialist evaluation.
After a single intramuscular injection, paliperidone is gradually released from the depot and detectable in plasma for up to 18 weeks (126 days). The median elimination half-life of the injectable form ranges from 25 to 49 days, which is considerably longer than the 24 hour half-life of oral paliperidone. This extended-release profile is what allows once-monthly dosing, but also means that both therapeutic effects and side effects persist for weeks after the last injection. Patients switching away from Paliperidon Teva should expect a prolonged tapering of drug levels during this window.
Paliperidon Teva and Invega Sustenna (also marketed as Xeplion in Europe) both contain the same active ingredient, paliperidone palmitate, as a once-monthly depot injection and are considered bioequivalent. Paliperidon Teva is a generic version that became available in Europe after the originator product lost market exclusivity. The clinical effects, dosing, side effects, and safety profile are therefore essentially the same. Switching between the branded and generic version should still be done under medical supervision, particularly if a patient is clinically stable on one specific product.
If the second initiation dose (day 8) is delayed by up to 4 days, the dose can still be given as soon as possible. If delays exceed this window, re-initiation may be needed. For monthly maintenance doses, delays of less than 6 weeks usually only require resuming the normal dose, while delays between 6 weeks and 6 months often require a dose in the deltoid followed one week later by the same dose, again in the deltoid, before returning to the normal monthly schedule. Delays of more than 6 months require restarting the full initiation regimen. Contact the treating psychiatric team immediately if an injection is missed, because delayed treatment increases the risk of psychotic relapse.
Weight gain is a recognised side effect of paliperidone and can occur with Paliperidon Teva, although typically less pronounced than with olanzapine or clozapine. Clinical trials report weight gain of 7 percent or more of baseline body weight in approximately 9 to 17 percent of patients after 12 months of treatment. Regular monitoring of weight, waist circumference, fasting glucose and lipid profile is recommended throughout treatment. Lifestyle interventions, including nutrition and physical activity, should be incorporated into the care plan from the start of therapy, and if significant metabolic change occurs, a switch to a more weight-neutral antipsychotic such as aripiprazole may be considered.
Yes. Paliperidone is a strong dopamine D2 antagonist in the tuberoinfundibular pathway and commonly elevates serum prolactin. This may cause breast enlargement, galactorrhoea (milk production) in men and women, menstrual irregularity or amenorrhoea, reduced libido, or erectile dysfunction. Persistent hyperprolactinaemia can also contribute to reduced bone mineral density over time. Prolactin-related symptoms should be discussed with the prescriber, as dose reduction, switching to a more prolactin-sparing antipsychotic such as aripiprazole, or specialist endocrine review may be required. Baseline and periodic prolactin measurement may be considered in symptomatic patients.
Alcohol should be avoided or strictly limited while on Paliperidon Teva. Alcohol adds to the sedating and cognitive effects of paliperidone, increases the risk of falls due to orthostatic hypotension, and can worsen the underlying psychiatric condition. It may also interact with associated medications such as benzodiazepines or mood stabilisers. Patients with a concurrent alcohol or substance use disorder should discuss an integrated treatment plan with their mental health team.
References
- European Medicines Agency (EMA). Xeplion (paliperidone palmitate) – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu/en/medicines/human/EPAR/xeplion
- U.S. Food and Drug Administration (FDA). Invega Sustenna (paliperidone palmitate) Prescribing Information. Reference ID: 4897645. Available at: www.accessdata.fda.gov
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List (2023). Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Updated 2024.
- Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39-59. doi:10.1007/s40263-020-00779-5
- Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387-404. doi:10.1016/S2215-0366(21)00039-0
- Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-117. doi:10.1016/j.schres.2009.10.026
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3
- Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686-693. doi:10.1001/jamapsychiatry.2017.1322
- British National Formulary (BNF). Paliperidone. NICE Evidence Services. Updated 2025. Available at: bnf.nice.org.uk/drugs/paliperidone
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Psychiatry and Clinical Pharmacology with documented academic background and clinical experience in long-acting injectable antipsychotics.
Medical Review
iMedic Medical Review Board – Independent panel of physicians who verify medical accuracy, evidence quality, and adherence to international guidelines (WHO, EMA, FDA, NICE, BNF).
Evidence Standard
Level 1A evidence based on systematic reviews, meta-analyses, and randomized controlled trials. GRADE evidence framework applied. No commercial funding.
Accessibility
Content reviewed for WCAG 2.2 Level AAA compliance. Optimized for screen readers, keyboard navigation, and assistive technology. High contrast support enabled.
Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.